Seattle-based InDi, aka Integrated Diagnostics, is planning to graduate from startup mode this year and start selling its first product, a diagnostic test that spots lung cancer in a tiny sample of blood. But before it does that, it has decided to spin out some of its key intellectual property into a new startup called InDi Molecular. The spinoff has secured a $1.5 million seed investment from InterWest Partners—one of the parent company’s venture backers from five years ago—as well as several angel investors.
Help employers find you! Check out all the jobs and post your resume.
